Immunomodulatory activity of glycodelin: implications in allograft rejection

Dixit, A and Balakrishnan, B and Karande, A A (2018) Immunomodulatory activity of glycodelin: implications in allograft rejection. In: CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 192 (2). pp. 213-223.

PDF Cli_Exp_Imm_192-9_213_2018.pdf - Published Version Restricted to Registered users only Download (564kB) | Request a copy

Abstract

Glycodelin is an immunomodulator, indispensable for the maintenance of pregnancy in humans. The glycoprotein induces apoptosis in activated CD4(+) T cells, monocytes and natural killer (NK) cells, and suppresses the activity of cytotoxic T cells, macrophages and dendritic cells. This study explores the immunosuppressive property of glycodelin for its possible use in preventing graft rejection. Because glycodelin is found only in certain primates, the hypothesis was investigated in an allograft nude mouse model. It is demonstrated that treatment of alloactivated mononuclear cells with glycodelin thwarts graft rejection. Glycodelin decreases the number of activated CD4(+) and CD8(+) cells and down-regulates the expression of key proteins known to be involved in graft demise such as granzyme-B, eomesodermin (EOMES), interleukin (IL)-2 and proinflammatory cytokines tumour necrosis factor (TNF)-alpha and IL-6], resulting in a weakened cell-mediated immune response. Immunosuppressive drugs for treating allograft rejection are associated with severe side effects. Glycodelin, a natural immunomodulator in humans, would be an ideal alternative candidate.

Item Type:	Journal Article
Publication:	CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Publisher:	WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
Additional Information:	Copy right for this article belong to WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
Department/Centre:	Division of Biological Sciences > Biochemistry
Date Deposited:	08 May 2018 19:03
Last Modified:	25 Aug 2022 08:17
URI:	https://eprints.iisc.ac.in/id/eprint/59816

Actions (login required)

View Item